Staying targeted on gene therapy

Targeted Genetics Corp. believes it has found a way to monetize its backburnered cell therapy technologies by spinning out the platform into its CellExSys subsidiary. But the gains will not be immediate, as TGEN expects that CellExSys will have to marinate in

Read the full 422 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE